Compare AbbVie Inc (ABBV) vs Moody's Corporation (MCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Moody's Corporation — how do they compare? AbbVie Inc trades at $253.85 (market cap $449.91B), while Moody's Corporation trades at $487.4 (market cap $87.42B). The key difference: AbbVie Inc is far larger — about 5.1× Moody's Corporation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | MCO | |
|---|---|---|
Market Cap | $449.91B | $87.42B |
Sector | Health | Financials |
52-Week High | $261.07 | $539.61 |
52-Week Low | $184.85 | $412.23 |
Enterprise Value | $513.38B | $93.23B |
Dividend Yield | 2.72% | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Moody's Corporation (MCO) trades at $500.49, up 2.03% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 31.69% net margins and consistent earnings beats, while trading at premium valuations (P/E 35.78). Recent AI integration announcements and dividend payments highlight strategic growth initiatives.
MCO presents a compelling growth story with strong profitability and analyst support (56% buy ratings, $542 consensus target), though elevated valuations and RSI overbought signals warrant caution. Key risks include competitive pressures and market sensitivity to credit cycles, but the company's market position and AI strategy support long-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
